The role of KLF6 and its splice variants in cancer therapy

Drug Resistance Updates

Volumn 12, Issue 1-2, 2009, Pages 1-7

  DiFeo, Analisa ^a   Martignetti, John A ^a   Narla, Goutham ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alternative mRNA splicing; Apoptosis; siRNA targeting; Tumor suppressor gene

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; ISOPROTEIN; KRUPPEL LIKE FACTOR 6; PROTEIN C JUN; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER THERAPY; GENE OVEREXPRESSION; GENE TARGETING; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; RNA SPLICING; SOMATIC MUTATION; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASMS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 62949123360     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2008.11.001     Document Type: Article

References (89)

1. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26 (2008) 561-569
2. Ars E., Serra E., García J., Kruyer H., Gaona A., et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum. Mol. Genet. 9 (2000) 237-247
3. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
4. Bartke T., Siegmond D., Peters N., Reichwein M., Henkler F., et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20 (2001) 571-580
5. Benzeno S., et al. Cyclin dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 64 (2004) 3885-3891
6. Bieker J.J. Kruppel-like factors: three fingers in many pies. J. Biol. Chem. 276 (2001) 34355-34358
7. Bitko V., Musiyenko A., Shulyayeva O., and Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11 (2005) 50-55
8. Botella L.M., Sanchez-Elsner T., Sanz-Rodriguez F., Kojima S., Shimada J., Guerrero-Esteo M., et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 100 (2002) 4001-4010
9. Cáceres J.F., and Kornblihtt A.R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18 (2002) 186-193
10. Camacho-Vanegas O., Narla G., Teixeira M.S., DiFeo A., Misra A., et al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int. J. Cancer 121 (2007) 1390-1395
11. Chen C., Hytinen E.R., Sun X., Helin H.J., Koivisto P.A., Frierson H.F., et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am. J. Pathol. 162 (2003) 1349-1354
12. Chen H.K., Liu X.Q., Lin J., Chen T.Y., Feng Q.S., Zeng Y.X., et al. Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 21 (2002) 1047-1050
13. Chiambaretta F., Blanchon L., Rabier B., Kao W.W., Liu J.J., Dastugue B., Rigal D., and Sapin V. Regulation of corneal keratin-12 gene expression by the human Kruppel-like transcription factor 6. Invest. Ophthalmol. Vis. Sci. 43 (2002) 3422-3429
14. Cho Y.G., Kim C.J., Park C.H., Yang Y.M., Kim S.Y., Nam S.W., et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24 (2005) 4588-4590
15. Dang D.T., Pevsner J., and Yang V.W. The biology of the mammalian Kruppel-like family of transcription factors. Int. J. Biochem. Cell Biol. 32 (2000) 1103-1121
16. Das A., Fernandez-Zapico M.E., Cao S., et al. Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J. Biol. Chem. 281 (2006) 39105-39113
17. de Fougerolles A., et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6 (2007) 443-453
18. Dedrick R., Myers C., Bungay P.M., et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62 (1978) 1-11
19. DeVincenzo J., Cehelsky J.E., Alvarez R., et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77 (2008) 225-231
20. DiFeo A., Feld L., Rodriguez E., et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 68 (2008) 965-970
21. DiFeo A., Narla G., Camacho-Vanegas O., et al. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25 (2006) 6026-6031
22. DiFeo A., Narla G., Hirshfeld J., et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin. Cancer Res. 12 (2006) 3730-3739
23. El Rouby S., Rao P.H., and Newcomb E.W. Assignment of the human B-cell-derived (BCD1) proto-oncogene to 10p14-p15. Genomics 43 (1997) 395-397
24. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
25. Ellis L.M., and Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8 (2008) 577-591
26. Faustino N.A., and Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev. 17 (2003) 419-437
27. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11915-11920
28. Garcia-Blanco M.A., Baraniak A.P., and Lasda E.L. Alternative splicing in disease and therapy. Nat. Biotechnol. 22 (2004) 535-546
29. Gewirtz A.M. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest. 117 (2007) 3612-3614
30. Glinsky G.V., et al. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113 (2004) 913-923
31. Gloor H. Arch. Julius Klaus-Stift 25 (1950) 38-44
32. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
33. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13 (1999) 1899-1911
34. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
35. Hartel M., Narla G., Wente M.N., et al. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur. J. Cancer 44 (2008) 1895-1903
36. Hastings M.L., Resta N., Traum D., Stella A., Guanti G., and Krainer A.R. An LKB1 AT-AC intron mutation causes Peutz-Jeghers syndrome via splicing at noncanonical cryptic splice sites. Nat. Struct. Mol. Biol. 12 (2005) 54-59
37. Inuzuka H., et al. Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem. Biophys. Res. Commun. 265 (1999) 664-668
38. Ito G., Uchiyama M., Kondo M., Mori S., Usami N., Maeda O., et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 64 (2004) 3838-3843
39. Jeng Y.M., and Hsu H.C. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int. J. Cancer 105 (2003) 625-629
40. Johnson J.M., Castle J., Garrett-Engele P., Kan Z., Loerch P.M., et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302 (2003) 2141-2144
41. Kettunen E., et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet. Cytogenet. 149 (2004) 98-106
42. Kim Y., Ratziu V., Choi S.G., Lalazar A., Theiss G., et al. Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J. Biol. Chem. 273 (1998) 33750-33758
43. Kojima S., Hayashi S., Shimokado K., Suzuki Y., Shimada J., Crippa M.P., and Friedman S.L. Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells. Blood 95 (2000) 1309-1316
44. Koritschoner N.P., Bocco J.L., Panzetta-Dutari G.M., Dumur C.I., Flury A., and Patrito L.C. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J. Biol. Chem. 272 (1997) 9573-9580
45. Kremer-Tal S., Narla G., Chen Y., Hod E., DiFeo A., et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol. 46 (2007) 645-654
46. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem. Soc. Symp. 66 (1999) 1-15
47. Li D., Yea S., Dolios G., Martignetti J.A., Narla G., et al. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J. Biol. Chem. 280 (2005) 26941-26952
48. Macleod K., Mullen P., Sewell J., Rabiasz G., Lawrie S., et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65 (2005) 6789-6800
49. Matsumoto N., Kubo A., Liu H., Akita K., Laub F., et al. Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107 (2006) 1357-1365
50. Mazoyer S., Puget N., Perrin-Vidoz L., Lynch H.T., Serova-Sinilnikova O.M., and Lenoir G.M. A BRCA1 nonsense mutation causes exon skipping. Am. J. Hum. Genet. 62 (1998) 713-715
51. McNamara II J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24 (2006) 1005-1015
52. Mercatante D.R., Mohler J.L., and Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem. 277 (2002) 49374-49382
53. Merika M., and Orkin S.H. Functional synergy and physical interactions of the erythroid transcription factor GATA-1 with the Kruppel family proteins Sp1 and EKLF. Mol. Cell Biol. 15 (1995) 2437-2447
54. Miller I.J., Bieker J.J., et al. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol. Cell Biol. 13 (1993) 2776-2786
55. Modrek B., and Lee C. A genomic view of alternative splicing. Nat. Genet. 30 (2002) 13-19
56. Mollinedo F., and Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist. Updates 9 (2006) 51-73
57. Narla G., DiFeo A., Reeves H.L., Schaid D.J., Hirshfeld J., Hod E., et al. A germline DNA polymorphism associated with increased prostate cancer risk enhances alternative splicing of the KLF6 tumor suppressor gene. Cancer Res. 65 (2005) 1213-1222
58. Narla G., DiFeo A., Yao S., et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65 (2005) 5761-5768
59. Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294 (2001) 2563-2566
60. Narla G., DiFeo A., Fernandez Y., et al. KLF-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118 (2008) 2711-2721
61. Oates A.C., Pratt S.J., Vail Y.I., Ho R.K., Johnson S.L., et al. The zebrafish klf gene family. Blood 98 (2001) 1792-1801
62. Okano J., Opitz O.G., Nakagawa H., Jenkins T.D., Friedman S.L., and Rustgi A.K. The Kruppel-like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact. FEBS Lett. 473 (2000) 95-100
63. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., and Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 13 (2006) 464-477
64. Peng D., Sheta E.A., Powell S.M., Moskaluk C.A., Washington K., Goldknopf I.L., and El-Rifai W. Alterations in Barrett's-related adenocarcinomas: a proteomic approach. Int. J. Cancer 122 (2008) 1303-1310
65. Philipsen S., and Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucl. Acids Res. 27 (1999) 2991-3000
66. Reeves H.L., Narla G., Ogunbiyi O., Haq A.I., Katz A., Benzeno S., et al. Kruppel-like factor 6 (KLF6) is a tumor suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126 (2004) 1090-1103
67. Schwerk C., and Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 19 (2005) 1-13
68. Shin C., and Manley J.L. Cell signaling and the control of pre-mRNA splicing. Nat. Rev. Mol. Cell. Biol. 5 (2004) 727-738
69. Sirach E., Bureau C., Peron J.M., Pradayrol L., Vinel J.P., et al. KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ. 14 (2007) 1202-1210
70. Slavin D.A., Koritschoner N.P., Prieto C.C., Lopez-Diaz F.J., Chatton B., Bocco J.L., et al. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene 23 (2004) 8196-8205
71. Song C.Z., Keller K., Chen Y., and Stamatoyannopoulos G. Functional interplay between CBP and PCAF in acetylation and regulation of transcription factor KLF13 activity. J. Mol. Biol. 329 (2003) 207-215
72. Sur I., Unden A.B., and Toftgard R. Human Kruppel-like factor5/KLF5: synergy with NF-kappaB/Rel factors and expression in human skin and hair follicles. Eur. J. Cell Biol. 81 (2002) 323-334
73. Tal-Kremer S., Reeves H.L., Narla G., Thung S.N., Schwartz M., Difeo A., et al. Frequent inactivation of the tumor suppressor Kruppel-like Factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40 (2004) 1047-1052
74. Teixeira M.S., Camacho-Vanegas O., Fernandez Y., et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int. J. Cancer 121 (2007) 1976-1983
75. Thorburn A., Behbakht K., and Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist. Updates 11 (2008) 17-24
76. Trimble E.L., Thompson S., Christian M.C., and Minasian L. Intraperitoneal chemotherapy for women with epithelial ovarian cancer. Oncologist 13 (2008) 403-409
77. Turner J., and Crossley M. Mammalian Krüppel-like transcription factors: more than just a pretty finger. Trends Biochem. Sci. 24 (1999) 236-240
78. van Deutekom J.C., Janson A.A., Ginjaar I.B., Frankhuizen W.S., Aartsma-Rus A., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. New Engl. J. Med. 357 (2007) 2677-2686
79. Van Hensbergen Y., Broxterman H.J., Hanemaaijer R., et al. Soluble aminopeptidase N/CD13 in malignant and non-malignant effusions and intratumoral fluid. Clin. Cancer Res. 8 (2002) 3747-3754
80. Wang S., Chen X., Zhang W., and Qiu F. KLF6mRNA expression in primary hepatocellular carcinoma. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24 (2004) 585-587
81. Willemse P.H., and de Vries E.G. Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. Drug Resist. Updates 6 (2003) 165-167
82. Yamashita K., et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2 (2002) 485-495
83. Yea S., Narla G., Zhao X., Garg R., Tal-Kremer S., Hod E., et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134 (2008) 1521-1531
84. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 20 (2001) 812-818
85. Zha J., Harada H., Osipov K., Jockel J., Waksman G., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-xl. Cell 87 (1996) 619-628
86. Zhang L., Ming L., and Yu J. BH3 mimetics to improve cancer therapy: mechanisms and examples. Drug Resist. Updates 10 (2007) 207-217
87. Zhang D., Zhang X.L., Michel F.J., Blum J.L., Simmen F.A., and Simmen R.C. Direct interaction of the Kruppel-like family (KLF) member, BTEB1, and PR mediates progesterone-responsive gene expression in endometrial epithelial cells. Endocrinology 143 (2002) 62-73
88. Zhang W., Shields J.M., Sogawa K., Fujii-Kuriyama Y., and Yang V.W. The gut-enriched Kruppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion. J. Biol. Chem. 273 (1998) 17917-17925
89. Zhao J.L., Austen K.F., and Lam B.K. Cell-specific transcription of leukotriene C(4) synthase involves a Kruppel-like transcription factor and Sp1. J. Biol. Chem. 275 (2000) 8903-8910